AlzProtect, planning its entry into phase 2, appoints Noëlle CALLIZOT as director of pharmaceutical development.

March, 26 2018

Lille (France), March 26th 2018 – ALZPROTECT, Biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease, announced today the hiring of its director of pharmaceutical development.

Noëlle Callizot is an international expert in the pharmaceutical and biotech industry. For 20 years, she has enabled the pharmaceutical development of neuroactive molecules up to advanced clinical stage. As director of neuropharmacology in the UK for 6 years, she has led various programs in neurodegenerative diseases (Alzheimer's, Parkinson's, etc.). Noëlle Callizot is co-founder of 4 biotech companies in fields as varied as contract research, functional neuro-rehabilitation, screening and neuro-active molecules. President of the AFMTELETHON Pharma Commission, Ms. Callizot also chairs several strategic programs for the AFM.

Noëlle Callizot will put into practice her experience in preclinical and clinical pharmaceutical R & D in the field of neurodegeneration.

"Dr. Callizot has extensive experience in pharmaceutical development in the complex field of neurodegenerative diseases which is a valuable addition to the company's next clinical stages" said Dr. Philippe Verwaerde, President of AlzProtect. Dr. Laurent Dupire, General Manager, added that “her expertise in the field of research, management and knowledge of scientific networks will enable AlzProtect to effectively address the next stages of its development.”

Noelle Callizot said "I was convinced by the potential of the AZP2006 whose original mechanism of action and impressive results allow to consider effective treatment of neurodegenerative diseases and in particular PSP. We look forward to testing its potential in the next Phase 2 ".

All news